Files and links (1)
CC BY V4.0, Open Access
Journal article
The relationship between patient-reported and clinician-assessed outcome measures in Inclusion body myositis - insights from a retrospective cohort study
Neuromuscular disorders : NMD, Vol.46, 105272
2025
PMID: 39799668
Appears in Open Access via Read & Publish Agreements
Abstract
Inclusion body myositis (IBM) is an inflammatory myopathy, characterised by slow progression of weakness, skeletal muscle atrophy, and heterogeneous clinical presentation. This variability in disease progression and presentation complicates tracking of clinical progress and intervention response in clinical trials, presenting challenges in identifying reliable outcome measures. We aimed to identify the most useful suite of clinician-assessed and patient-reported outcome measures (PROMs) for use in clinical practice and trials from a selection of the most commonly used outcome measures in IBM. We retrospectively analysed clinician-assessed outcome measures (manual muscle testing (MMT8, MMT12)), right- and left-handed grip strength, modified timed up and go (mTUG), two-minute walk test (2MWT); a clinician-administered patient-reported tool (IBM Functional Rating Scale (IBMFRS)); and PROMs including the eating assessment tool (EAT-10), and neuromuscular symptom score (NSS) from 20 participants attending a single specialist myositis clinic in Perth, Australia. Correlation analysis revealed significant correlations between the IBMFRS, MMT8, MMT12, mTUG and 2MWT (p < 0.05). The NSS strongly correlated with the MMT8, MMT12 and 2MWT (p < 0.05). Univariate regression analyses revealed that 2MWT, MMT12 and mTUG were significant predictors of the IBMFRS and NSS, and backward stepwise linear regression highlighted that the 2MWT was a significant positive predictor for the IBMFRS (p < 0.001). Overall, we concluded that the IBMFRS, NSS, 2MWT and mTUG models were the best predictors of patient-perceived physical function in IBM.
Details
- Title
- The relationship between patient-reported and clinician-assessed outcome measures in Inclusion body myositis - insights from a retrospective cohort study
- Authors/Creators
- Madeline Schopp - The University of Notre Dame AustraliaKelly Beer - Fiona Stanley HospitalIan Cooper - Perron Institute for Neurological and Translational ScienceKathryn Hird - The University of Notre Dame AustraliaAlthea Doverty - Murdoch University, Centre for Molecular Medicine and Innovative TherapeuticsAnnik Panicker - Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, AustraliaKatie Schütze - The University of Notre Dame AustraliaAnna Brusch - Sir Charles Gairdner HospitalMerrilee Needham - Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics
- Publication Details
- Neuromuscular disorders : NMD, Vol.46, 105272
- Publisher
- Elsevier B.V.
- Number of pages
- 8
- Identifiers
- 991005732486107891
- Copyright
- © 2024 The Author(s).
- Murdoch Affiliation
- Centre for Molecular Medicine and Innovative Therapeutics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
119 File views/ downloads
37 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.106 Rheumatology
- 1.106.1684 Dermatomyositis
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- ESI research areas
- Neuroscience & Behavior